Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 3, 2009

HemCon and Prometic to Develop Capture Device for Antibody Removal

HemCon and Prometic to Develop Capture Device for Antibody Removal

HemCon and Prometic enter development agreement

  • HemCon Medical Technologies entered an agreement with ProMetic BioScience for a sterile, single-use antibody capture device for the removal of isoagglutinin antibodies. The device will be based on ProMetic's affinity absorbent technology and will be for single-source and pooled plasma in combination with HemCon's Lycophilized Plasma (LyP) System.

    If the device is successfully combined with the LyP System, which is also under development, the product could represent a global revenue opportunity in excess of $500 million a year by 2012, says HemCon.

    Under the agreement, HemCon will fund the development program. Both companies will jointly own all technology resulting from the partnership, with HemCon retaining exclusive purchasing rights and ProMetic, the U.K.-based division of ProMetic Life Sciences, the sole supplier for the LyP System.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »